Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | |||
Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | |||
Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | |||
VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn | |||
Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Withdrawn | |||
Xolair | Omalizumab | Asthma, severe persistent | Cancelled |